Entity
  • NIOX®

    Created in 2006
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    298 10,888
  • Activities

  • Technologies

  • Entity types

  • Location

    Edmund Halley Rd, Littlemore, Oxford OX4, UK

    The Oxford Science Park

    United Kingdom

  • Employees

    Scale: 51-200

    Estimated: 124

  • Engaged corporates

    4
    1 1
  • Added in Motherbase

    3 years ago
Description
  • Value proposition

    NIOX Group plc is a dedicated diagnostics and monitoring company focused on respiratory disease.

    NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX VERO®, is a non-invasive medical device that measures fractional exhaled nitric oxide (FeNO) levels in patients with asthma.

    NIOX VERO® provides accurate and reliable results, allowing healthcare
    professionals to make informed decisions about the diagnosis and management of asthma. It is easy to use, and can be used in a variety of settings, including clinics, hospitals, and primary care settings.

    The NIOX Group plc is committed to improving the lives of people with asthma and is dedicated to innovation and excellence in its products and services. NIOX® is also committed to offering additional training and support for healthcare professionals.

    Overall, NIOX Group plc is the global leader in FeNO testing, with a strong
    reputation for innovation and excellence in the development of medical devices for the diagnosis and management of asthma. With NIOX VERO®, healthcare professionals have a reliable and non-invasive tool to help them better diagnose and manage asthma.

    References:
    1. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-218.
    2. Gao J et al. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy, Asthma & Clinical Immunology. 2018;1
    3. Busse WW et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165-1173.
    4. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633.
    5. NIOX®. Data on File; MKT-DOF-007.

    FeNO testing, NIOX®, Asthma management, and Asthma diagnosis

  • NIOX VERO®, the simplest way to test FeNO – NIOX.com

    Find out more about NIOX VERO®, the gold standard FeNO analyser from NIOX®, the world-leader in FeNO testing – NIOX.com

  • https://www.niox.com/en/
Corporate interactions BETA
Corporate TypeTweets Articles
Intuitive
Intuitive
Medical Device, Medical Equipment Manufacturing
Intuitive
Medical Device, Medical Equipment Manufacturing
Other

23 Jul 2021


Oxford Science Enterprises
Oxford Science Enterprises
Startup accelerator & VC, Venture Capital and Private Equity Principals
Oxford Science Enterprises
Startup accelerator & VC, Venture Capital and Private Equity Principals
Other

2 Apr 2019


London Stock Exchange
London Stock Exchange
Finance, Financial Services
London Stock Exchange
Finance, Financial Services
Not capitalistic
Not partnership
Event

20 Mar 2014


IP Group plc
IP Group plc
Financial Services
IP Group plc
Financial Services
Other

2 Apr 2019


Similar entities
Loading...
Loading...
Social network dynamics